Y-mAbs Therapeutics (YMAB) Revenue & Revenue Breakdown
Y-mAbs Therapeutics Revenue Highlights
Latest Revenue (Y)
$87.69M
Latest Revenue (Q)
$20.90M
Main Segment (Y)
Product
Main Geography (Y)
UNITED STATES
Y-mAbs Therapeutics Revenue by Period
Y-mAbs Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $87.69M | 3.38% |
| 2023-12-31 | $84.82M | 29.96% |
| 2022-12-31 | $65.27M | 87.03% |
| 2021-12-31 | $34.90M | 68.18% |
| 2020-12-31 | $20.75M | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | - |
Y-mAbs Therapeutics generated $87.69M in revenue during NA 2024, up 3.38% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Y-mAbs Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-03-31 | $20.90M | -21.10% |
| 2024-12-31 | $26.50M | 43.52% |
| 2024-09-30 | $18.46M | -19.02% |
| 2024-06-30 | $22.80M | 14.38% |
| 2024-03-31 | $19.93M | -14.69% |
| 2023-12-31 | $23.36M | 14.22% |
| 2023-09-30 | $20.45M | -1.43% |
| 2023-06-30 | $20.75M | 2.47% |
| 2023-03-31 | $20.25M | -35.60% |
| 2022-12-31 | $31.45M | 150.83% |
| 2022-09-30 | $12.54M | 16.12% |
| 2022-06-30 | $10.80M | 2.97% |
| 2022-03-31 | $10.49M | 9.25% |
| 2021-12-31 | $9.60M | 7.06% |
| 2021-09-30 | $8.96M | -18.14% |
| 2021-06-30 | $10.95M | 103.44% |
| 2021-03-31 | $5.38M | -74.06% |
| 2020-12-31 | $20.75M | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | - |
Y-mAbs Therapeutics generated $20.90M in revenue during Q1 2025, up -21.10% compared to the previous quarter, and up 89.47% compared to the same period a year ago.
Y-mAbs Therapeutics Revenue Breakdown
Y-mAbs Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|
| Product | $85.19M | $84.32M | $49.27M | $32.90M |
| License | $2.50M | $500.00K | $16.00M | $2.00M |
Y-mAbs Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 24: Product (97.15%), and License (2.85%).
Quarterly Revenue by Product
| Product/Service | Mar 25 | Dec 24 | Sep 24 | Mar 24 | Dec 23 | Jun 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product | $20.90M | $47.29M | $18.46M | $19.43M | $63.57M | $20.75M | $16.45M | $12.54M | $9.80M | $9.60M | $8.96M | $8.95M | $5.38M | - |
| License | - | $1.50M | $500.00K | $500.00K | $15.00M | - | $1.00M | - | - | $2.00M | - | - | - | - |
| Product, DANYELZA | - | - | - | - | - | $2.52M | $10.49M | - | - | - | - | - | - | - |
Y-mAbs Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Mar 25: Product (100.00%).
Y-mAbs Therapeutics Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 24 | Dec 23 | Dec 22 |
|---|---|---|---|
| Eastern Asia | $7.46M | - | - |
| Western Europe | $2.09M | - | - |
| UNITED STATES | $65.98M | $67.81M | - |
| Non-US, Other | $890.00K | - | - |
| Non-US | $19.20M | $16.50M | - |
| Latin America | $4.72M | - | - |
| United States | - | - | $46.26M |
| Other countries | - | - | $3.01M |
Y-mAbs Therapeutics's latest annual revenue breakdown by geography, as of Dec 24: UNITED STATES (65.76%), Non-US (19.14%), Eastern Asia (7.43%), Latin America (4.70%), Western Europe (2.08%), and Non-US, Other (0.89%).
Quarterly Revenue by Country
| Country | Mar 25 | Dec 24 | Sep 24 | Mar 24 | Jun 23 | Mar 23 |
|---|---|---|---|---|---|---|
| Non-US, Other | $165.00K | $38.00K | $852.00K | - | - | - |
| Non-US | $7.52M | $15.25M | $3.13M | $821.00K | - | - |
| Latin America | $2.01M | $3.44M | $1.27M | - | - | - |
| Eastern Asia | $1.51M | $6.45M | $1.01M | - | - | - |
| UNITED STATES | $13.38M | $32.04M | $15.33M | $18.61M | - | - |
| Western Europe | - | - | $2.09M | - | - | - |
| CHINA | - | - | - | - | $3.54M | - |
| United States | - | - | - | - | $15.85M | $16.83M |
| Other countries | - | - | - | - | $4.90M | $3.42M |
| Europe | - | - | - | - | - | $2.52M |
Y-mAbs Therapeutics's latest quarterly revenue breakdown by geography, as of Mar 25: UNITED STATES (54.42%), Non-US (30.59%), Latin America (8.19%), Eastern Asia (6.13%), and Non-US, Other (0.67%).
Y-mAbs Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| MIRM | Mirum Pharmaceuticals | $336.89M | $99.41M |
| TVTX | Travere Therapeutics | $233.18M | $81.73M |
| ARQT | Arcutis Biotherapeutics | $196.54M | $71.36M |
| DAWN | Day One Biopharmaceuticals | $131.16M | $29.21M |
| YMAB | Y-mAbs Therapeutics | $87.69M | $20.90M |
| BLUE | bluebird bio | $83.81M | $38.52M |
| ZNTL | Zentalis Pharmaceuticals | $67.42M | $26.86M |
| STRO | Sutro Biopharma | $62.04M | $14.81M |
| MRSN | Mersana Therapeutics | $40.50M | $12.60M |
| MRUS | Merus | $36.13M | $9.14M |
| SNDX | Syndax Pharmaceuticals | $23.68M | $20.04M |
| CCCC | C4 Therapeutics | $20.76M | $5.18M |
| GBIO | Generation Bio | $19.89M | $4.19M |
| KRON | Kronos Bio | $9.85M | $2.27M |
| BDTX | Black Diamond Therapeutics | - | - |
| PCVX | Vaxcyte | - | - |
| RVMD | Revolution Medicines | - | - |
| EWTX | Edgewise Therapeutics | - | - |
| ERAS | Erasca | - | - |
| PASG | Passage Bio | - | - |
| LRMR | Larimar Therapeutics | - | - |